Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice

Journal of Clinical Investigation

Volumn 115, Issue 2, 2005, Pages 428-433

  Brendza, Robert P ^a   Bacskai, Brian J ^b   Cirrito, John R ^a   Simmons, Kelly A ^a   Skoch, Jesse M ^b   Klunk, William E ^c   Mathis, Chester A ^c   Bales, Kelly R ^d   Paul, Steven M ^d   Hyman, Bradley T ^b   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[25-35]; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN; AMYLOID PRECURSOR PROTEIN; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DENDRITE; DYSTROPHY; GLIA CELL; IMAGE PROCESSING; MOUSE; MULTIPHOTON MICROSCOPY; NERVE FIBER DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PDAPP GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN STRUCTURE; SENILE PLAQUE; TRANSGENE; ANIMAL; GENETICS; IMMUNOLOGY; NEURITE; NEUROAXONAL DYSTROPHY; OPTICAL TOMOGRAPHY; PATHOLOGY; RADIOGRAPHY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES, MONOCLONAL; MICE; MICE, TRANSGENIC; NEURITES; NEUROAXONAL DYSTROPHIES; SENILE PLAQUES; TOMOGRAPHY, OPTICAL;

EID: 85047691873     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23269     Document Type: Article

References (35)

1. Sisodia, S.S. 1999. Alzheimer's disease: perspectives for the new millennium. J. Clin. Invest. 104:1169-1170.
2. Golde, T.E., Eckman, C.B., and Younkin, S.G. 2000. Biochemical detection of Abeta isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta. 1502:172-187.
3. Selkoe, D.J. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741-766.
4. McKee, A.C., Kosik, K.S., and Kowall, N.W. 1991. Neuritic pathology and dementia in Alzheimer's disease. Ann. Neurol. 30:156-165.
5. Grace, E.A., Rabiner, C.A., and Busciglio, J. 2002. Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. Neuroscience. 114:265-273.
6. Knowles, R.B., et al. 1999. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 96:5274-5279.
7. Le, R., et al. 2001. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J. Neuropathol. Exp. Neurol. 60:753-758.
8. Schenk, D., et al. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:173-177.
9. Janus, C., et al. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:979-982.
10. Bacskai, B.J., et al. 2001. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 7:369-372.
11. Bacskai, B.J., et al. 2002. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22:7873-7878.
12. Sigurdsson, E.M., Scholtzova, H., Mehta, P.D., Frangione, B., and Wisniewski, T. 2001. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am. J. Pathol. 159:439-447.
13. Morgan, D., et al. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:982-985.
14. DeMattos, R.B., et al. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98:8850-8855.
15. Bard, F., et al. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-919.
16. Lombardo, J.A., et al. 2003. Amyloid-β antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23:10879-10883.
17. Oddo, S., Billings, L., Kesslak, J.P., Cribbs, D.H., and LaFerla, F.M. 2004. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 43:321-332.
18. Wilcock, D.M., et al. 2004. Passive amyloid immunotherapy clears amyloid and transiently activates microgliain a transgenic mouse model of amyloid deposition. J. Neurosci. 24:6144-6151.
19. Wilcock, D.M., et al. 2004. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis. 15:11-20.
20. Christie, R., Kimchi, E., Kajdasz, S., Bacskai, B., and Hyman, B.T. 2001. Multiphoton microscopy and amyloid angiopathy. Amyloid. 8(Suppl. 1):48-50.
21. Christie, R.H., et al. 2001. Growth arrest of individual senile plaques in a model of Alzheimer's disease observed by in vivo multiphoton microscopy. J. Neurosci. 21:858-864.
22. Kimchi, E.Y., Kajdasz, S., Bacskai, B.J., and Hyman, B.T. 2001. Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy. J. Neuropathol. Exp. Neurol. 60:274-279.
23. D'Amore, J.D., et al. 2003. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J. Neuropathol. Exp. Neurol. 62:137-145.
24. Brendza, R.P., et al. 2003. PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures. J. Comp. Neurol. 456:375-383.
25. Klunk, W.E., et al. 2002. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 61:797-805.
26. Hardy, J., and Selkoe, D.J. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:353-356.
27. Holtzman, D.M., Bales, K.R., Paul, S.M., and DeMattos, R.B. 2002. Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv. Drug Deliv. Rev. 54:1603-1613.
28. Brendza, R.P., et al. 2003. Use of YFP to study amyloid-β associated neurite alterations in live brain slices. Neurobiol. Aging. 24:1071-1077.
29. Oddo, S., et al. 2003. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 39:409-421.
30. Stern, E.A., et al. 2004. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J. Neurosci. 24:4535-4540.
31. Dodart, J.C., et al. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:452-457.
32. Kotilinek, L.A., et al. 2002. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22:6331-6335.
33. Games, D., et al. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 373:523-527.
34. Feng, G., et al. 2000. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 28:41-51.
35. Chen, B.E., et al. 2000. Imaging high-resolution structure of GFP-expressing neurons in neocortex in vivo. Learn. Mem. 7:433-441.